EXEL — Exelixis, Inc. | SharesGrow.com

Exelixis, Inc. (EXEL) 是一家生物科技公司，屬於醫療保健產業, 目前交易價格為 $45.86. 其SharesGrow評分為 83/100, 表明強勁的投資特徵， 7項中通過6項.

SharesGrow calculates the intrinsic value of EXEL = $125.10 (+172.8% 相對於當前價格, 該股票看起來被低估). 分析師共識目標價為 EXEL = $44 (-3.8% 上漲空間).

估值: EXEL 本益比(P/E)為 15.3 (S&P 500平均約25) 前瞻PEG為 0.84.

財務數據: 營收為 $2.3B, +13%/yr 平均成長. 淨利潤為 $783M, 成長率為 +71.7%/yr. 淨利潤率為 33.7% (強勁). 毛利率為 96.4% (+0 pp 趨勢).

資產負債表: 總債務為 $173M 對比 $2.2B 股東權益 (D/E比率 0.08, 保守). 流動比率為 3.56 (流動性強). 資產負債率為 6.1%. 總資產: $2.8B.

分析師展望: 16 / 32 位分析師評級 EXEL 為買入 (50%) — 適度共識.

SharesGrow 7項標準細分: Value 74/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 76/100 (Pass), Future 38/100 (Fail), Income 100/100 (Pass).

$44.11

▼ 3.82% 下跌空間

Average Price Target

基於 32 位華爾街分析師對 Exelixis, Inc. 提供的12個月價格目標，平均目標價為 $44.11，最高預測為 $54.00，最低預測為 $30.00。

Highest Price Target

$54.00

Average Price Target

$44.11

Lowest Price Target

$30.00

EXEL SharesGrow 評分概覽

83/100

SharesGrow Score

Strong investment profile

View full scorecard →

價值 74/100

估值 — P/E, PEG, Forward PEG

成長 90/100

財務數據 — 平均成長

過去 100/100

強勁 — 趨勢

健康 100/100

資產負債表 — D/E比率, 流動比率為

護城河 76/100

毛利率為 + market cap

未來 38/100

分析師展望 — 為買入

收入 100/100

淨利潤率為

Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — EXEL

✓

價值 Pass

74/100

EXEL 本益比(P/E)為 15.3 (S&P 500平均約25). Forward PEG 0.84 — Peter Lynch 被低估 (≤1.0). Trailing PEG 0.87. 分析師共識目標價為 $44, 意味著 -4.1% 相對於當前價格 $46. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.

EXEL: +13%/yr 營收為, +71.7%/yr 淨利潤為平均成長. > 5%/yr — 強勁. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

EXEL: 4 / 4 年獲利. 強勁 — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

資產負債表 EXEL: D/E比率 0.08 (保守), 流動比率為 3.56 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

EXEL: 毛利率為 96.4% (+0 pp 趨勢), $12B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 76/100. ≥ 70 = Pass.

分析師展望: 16 / 32 位分析師評級 EXEL 為買入 (50%). 分析師共識目標價為 $44 (-4.1% 上漲空間). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.

EXEL: 淨利潤率為 33.7%. 強勁 (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

市場數據

52週區間32.38-49.62

成交量2.5M

30日平均成交量2.75M

市值$12.3B

Beta（1年）0.42

Share Statistics

EPS（TTM）2.88

流通股數$271.57M

IPO Date2000-04-17

Employees1,147

CEOMichael Morrissey

Financial Highlights & Ratios

Revenue (TTM)$2.32B

Gross Profit$2.24B

EBITDA$921.76M

Net Income$782.57M

Operating Income$872.19M

Total Cash$1.06B

Total Debt$173.04M

Net Debt$-309.45M

Total Assets$2.84B

Price / Earnings (P/E)15.9

Price / Sales (P/S)5.3

Analyst Forecast

1Y Price Target$44.00

Target High$54.00

Target Low$30.00

上漲空間-4.1%

評級共識Buy

覆蓋分析師數32

買入 50% 持有 50% 賣出 0%

Price Target Summary

公司資訊

國家US

交易所NASDAQ Global Select

貨幣USD

ISINUS30161Q1040

股價走勢

EXEL

Exelixis, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

32.38 52WK RANGE 49.62

其他人也在看

ALNY

Alnylam Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

BMRN

BioMarin Pharmaceutical Inc.

$55.47

+1.08%

HALO

Halozyme Therapeutics, Inc.

$67.31

+0.49%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

PTCT

PTC Therapeutics, Inc.

$73.01

+3.68%

Exelixis, Inc. EXEL NASDAQ

EXEL SharesGrow 評分概覽

評分明細 — EXEL

Stock Chart & Stats

股價走勢

其他人也在看

獲取低估股票提醒